



Vision Biotechnology Consulting Curriculum Vitae

Mark J. Sarno

mjsarno@cox.net

<http://members.aol.com/ldsarno/>

315 S. Coast Hwy 101, Suite U, PMB 144 ♦

Encinitas, CA 92024

(760) 634-2999 ♦ FAX: (760) 634-3233

Recent Experience and Results

- Consultant to Santarus Inc., San Diego, CA, September 2003-Present
 - Performed literature review on omeprazole pharmacodynamics and pharmacokinetics and composed sections of CTDs for suspension formulations of omeprazole – 20 mg dose approved by FDA 6/04; 40 mg dose approved 12/04
 - Authored Safety, PK, and PD sections of CTD submissions for capsule and tablet formulations of omeprazole
 - Authored pediatric PK/PD/safety clinical trial protocols
 - Authored protocol for randomized, crossover comparison of new omeprazole formulation versus Nexium in nocturnal acid breakthrough from gastroesophageal reflux disease
 - Performed 3rd party technical review/quality assurance of draft CTDs
 - Authored protocol for pharmacokinetic/pharmacodynamic study of immediate-release capsule formulation of omeprazole
 - Authored clinical trial reports for multiple PK/PD studies of suspension, capsule, and tablet formulations of omeprazole.
 - Authored clinical review of approved suspension formulations of omeprazole

- Consultant to ReliaLab Inc., Basking Ridge, NJ, September 2004-Present
 - Performed statistical analyses of clinical and analytical investigations comparing new rapid assay for lithium to predicate method; Results: Test received 510(k) approval in 3/05 and CLIA Waiver status in 4/05.

- Consultant to Chiltern International, San Diego, CA, March 2004-Present
 - Authored Phase I/II clinical trial protocol on organ rescue agent for use in breast cancer chemotherapy, including statistical plan development
 - Authored Investigator Brochure for organ rescue agent
 - Co-authored IND submission for organ rescue agent. IND approved 3/05. Drug also received fast-track FDA status 3/05.

- Consultant to diaDexus Inc., South San Francisco, CA, March 2001-Present
 - Analyzed Atherosclerosis Risk in Communities (ARIC) trial database via multiple stratifications using univariate and multivariate Cox regression and Kaplan-Meier methodologies to determine predictive capability of new cardiac risk factor; Results used in 510(k) submission – Clearance granted by FDA 7/03
 - Performed biostatistical analyses of cardiac event risk factor trial
 - Performed cluster regression to determine optimal configurations for new in vitro diagnostic test
 - Designed protocols and performed biostatistical analysis of biological variability, specificity, and reference range studies for in vitro diagnostic
 - Provided statistical guidance regarding robust variance estimations in case-cohort studies
 - Provided guidance on analytical characterization of in-vitro diagnostic componentry and determination of product specifications
 - Trained scientists in use of Factorial Design/Response Surface Modeling techniques and statistical analyses thereof
 - Performed biostatistical analyses to determine potential of multiple new tumor markers for prostate, ovarian, breast, colon, and lung cancer using univariate and multivariate logistic regression and Cox regression techniques
 - Analyzed ARIC trial database via multiple stratifications using univariate and multivariate Cox regression and Kaplan-Meier methodologies to determine predictive capability of new ischemic stroke risk factor and authored statistical sections of 510(k) submission (submitted to FDA in 1/05).

- Consultant to Tomen America Inc., New York, NY, April 2002-June 2004
 - Provided guidance on regulatory path for new diabetes monitoring test
 - Performed sample size determinations for longitudinal and cross-sectional studies of new diabetes monitoring test
 - Authored protocols for longitudinal and cross-sectional studies
 - Authored Pre-IDE submission to FDA detailing clinical development plan and proposed trials
 - Authored protocol for reference range study and performed statistical analyses on results
 - Performed biostatistical analyses on longitudinal trial
 - Authored product development summary detailing international transfer of technology and eventual domestic clinical trials
 - Co-authored 510(k) submission – Clearance granted by FDA 9/03
 - Managed business development activities to implement new test in multiple clinical laboratories nationwide

- Consultant to Gen-Probe Inc., San Diego, CA, September 2004-Present
 - Designed and authored clinical study protocols for development of new nucleic acid amplification assay for prostate cancer
- Consultant to Medikinetics, Inc., San Diego, CA, August 2003-Present
 - Authored continuing medical education monograph on the role of post-prandial hyperglycemia and oral hypoglycemic agents to control post-prandial hyperglycemia
 - Authored continuing medical education monograph on cardiovascular disease considerations in type II diabetes
 - Reviewed medical education manuscript on medication compliance in diabetes
 - Authored FAQ on effects of amylin and pramlintide on Glucagon and use of Glucagon for injection in diabetes-FAQ to be used on medical education website
- Consultant to Applied Imaging, Inc., San Jose, CA, November 2004-Present
 - Performed statistical analyses of clinical and analytical investigations comparing automated Her-2/neu imaging assay to manual method. Results submitted in 510(k) 12/04.
- Consultant to Metrika, Inc., Sunnyvale, CA, November 2004-Present
 - Performed sample size/power analysis for post-marketing trial of glycemic monitoring test
- Consultant to Qualigen, Inc. Carlsbad, CA, March 2005-Present
 - Reviewed statistical considerations for planned prostate cancer marker study and participated in discussions with FDA review team to finalize protocol.
- Consultant to Maxim Pharmaceuticals, San Diego, CA, May 1999-January 2005
 - Performed database design, data management, and statistical analysis of Phase I safety and pharmacokinetics trial
 - Performed statistical and pharmacokinetic analysis of Phase I trial in melanoma and renal cell carcinoma patients to determine drug-drug interactions for combination therapy
 - Performed pharmacokinetic analyses from studies in animal models and human subjects from Phase III melanoma trial
 - Managed physico-chemical characterization studies of drug substance including e.g. polymorphism, DSC, TGA, IR, NMR, MS, X-ray diffraction, solubility, etc.
 - Managed contract manufacturing of 5 process validation lots of injectable drug product.
 - Performed Kaplan-Meier and Proportional Hazards survival analyses from Phase III Melanoma Trial

- Performed statistical analysis to set release specifications and to initiate statistical process control
 - Performed sample size statistical determinations for Phase III clinical trials in malignant melanoma and hepatitis C
 - Performed sample size statistical determinations for Phase I/II clinical trial in oral mucositis
 - Performed statistical analyses of toxicokinetic studies in multiple animal species
 - Used factorial design and response surface model techniques to optimize new drug formulation for oral mucositis
 - Managed prototype development of potential new dosage form
 - Performed analytical chemistry and methods validation “Gap Analyses” in preparation of CMC sections of NDA and MAA
 - Performed pharmacodynamic analyses of new cancer immunotherapeutic
 - Managed drug substance manufacturing at multiple contract manufacturers
 - Authored protocols for validation of immunoassay methods
 - Provided technical guidance in experimental designs to optimize chemistry processing parameters
- Consultant to La Jolla Pharmaceutical Company, San Diego, CA, December 2002-Present
 - Co-authored report on use of screening test for categorization of patients who are likely to respond to new therapy for systemic lupus erythematosus (SLE) – Report included in NDA. Approvable letter received from FDA in 10/04.
 - Provided 3rd party review of validation protocols and reports for inclusion in NDA
 - Performed regulatory audit on development and validation of affinity assay
 - Authored development history report on pharmacoproteomic assay
- Grant reviewer on behalf of Lytmos, LLC, Lee’s Summit, MO, November 2003-Present
 - Reviewed SBIR, STTR, and NIH grant applications
- Consultant to DiagnoCure Inc., Ontario, Quebec, Canada, January 2003-December 2003
 - Ghost-wrote paper on new marker for prostate cancer
- Consultant/Chief Scientific Advisor to Equidyne Systems, San Diego, CA, June 1998-January 2004

- Designed, managed, monitored, and performed pharmacokinetic and biostatistical analyses on insulin PK trial
 - Designed, managed, monitored, and analyzed pediatric vaccine efficacy and pain study
 - Identified, contacted, and managed strategic alliances with 87 pharmaceutical companies for co-development and co-marketing activities
 - Performed molecular damage trial on drugs administered with jet injector; report used to solidify relationships with strategic partners
 - Designed and performed experimentation to optimize material compatibility of disposable ampule devices for potential pre-filling with various drug products
 - Designed clinical protocols and case report forms for Insulin PK trial, pediatric diabetes trial, and pain studies
 - Performed biostatistical analyses on long-term pediatric diabetes trial
- Consultant to MPEX Inc., San Diego, CA, July 2002-January 2003
 - Evaluated novel bioparticle technology vis a vis application to clinical diagnostics and high-throughput drug screening
- Consultant to Ancile Pharmaceuticals Inc., San Diego, CA, July 2002-January 2003
 - Provided 3rd party review of clinical program strategy and SBIR application for pharmacokinetic trial
- Consultant to Medlyte Inc., San Diego, CA, May 2002-January 2003
 - Provided guidance in optimization and reduction of variability in HPLC-based reference method for new cardiovascular analyte
 - Provided guidance in development of new immunoassay for novel cardiovascular risk factor/ischemia marker
- Consultant to Bio-hydration Research Lab, Inc., San Diego, CA, January 2002-November 2002
 - Developed statistical analysis plans for two clinical trials of super-oxygenated pentameric water
- Consultant to Pacific Biometrics, Inc., Seattle, WA, 1997-2002
 - Managed the project team developing a novel diagnostic test for pyridinoline crosslinks in human sweat
 - Managed the research team in the development, optimization, and validation of the pyridinoline immunoassay, which required significant increases in sensitivity and reproducibility
 - Managed the research team in the validation of the sweat patch collection device
 - Performed statistical analysis of clinical studies; Presented

- results to FDA Clinical Chemistry branch
 - Co-wrote the 510(k) submission
 - Performed oral and poster presentations of clinical studies at the 1997 and 1998 American Society of Bone and Mineral Research conference
 - Developed and implemented a Project Management process for development of diagnostic test
- Consultant to FeRx Incorporated, San Diego, CA, June 1998-June 1999
 - Performed statistical analysis of toxicology studies; analyses submitted in IND approved by FDA with no deficiencies cited by FDA biostatistics department
- Consultant to Ablation Technologies, Inc., San Diego, CA, April-May 1998
 - Designed case report forms for OUS study on implantable device for the thermal ablation of malignant prostate tissue
- Consultant to Adeza Biomedical, Inc., Sunnyvale, CA, July 1997-January 1998
 - Provided guidance in development and optimization of a dipstick assay for fetal fibronectin using factorial design techniques
- Consultant to Metra Biosystems, Mountain View, CA May-November 1996
 - Provided training presentations in the field of rheumatology to support Metra's entry into the field.
 - Coordinated the transfer of processes developed by a third party to Metra's Manufacturing facility.
 - Authored documentation including Manufacturing Documents, Standard Operating Procedures, and Testing Methods.
 - Provided methods for statistical analysis.
- NovaDx Incorporated, San Diego, CA March 1995- May 1996
As Director of Product Development,
 - Managed the development of an immunoassay for YKL-40, a novel biochemical marker found in high amounts in individuals with Rheumatoid Arthritis and Osteoarthritis.
 - Defined and implemented the overall Product Development process. This task included design and implementation of a Project Management process, generation of Product Designs and Manufacturing Documents, and implementation of Design Control
 - Assisted in the business development area, wherein I provided technical expertise and liaison with two major corporate partners, Abbott Laboratories and Metra Biosystems. The results of these endeavors were licensing agreements with these two parties to manufacture the immunoassay for YKL-40.

- Hybritech Incorporated, La Jolla, CA 1986-1995
 - 7 years in Product Development - Total of 11 Product launches as Scientist, Development Leader or Project Team Leader/Manager; Technologies and biochemical markers developed: immunoenzymetric and immunoradiometric assays for IgE, Ferritin, Thyroid Stimulating Hormone, Prostatic Acid Phosphatase, Luteinizing Hormone, Follicle Stimulating Hormone, Group B Streptococcus, Prostate Specific Antigen, Creatine Kinase MB isoenzyme, Colorectal Cancer Antigen CA-195, Deoxypyridinoline Crosslinks of bone collagen (chemiluminescent, radiometric, and colorimetric assays)
 - 2 years spent in a Manufacturing Technical Support capacity during which I was responsible for the manufacture of 10 diagnostic products including Hybritech's highest volume products, the Prostate Specific Antigen (PSA) radioimmunometric and enzyme-immunometric assays.
- Research Institute of Scripps Clinic, La Jolla, CA 1983-1986

Education

Bachelor of Arts in Biochemistry and Cell Biology
Conferred at the University of California at San Diego
June 1983

Technical and Managerial Expertise

Areas of Technical Expertise

- Familiarity with multiple clinical fields, e.g. cardiovascular disease, rheumatology, endocrinology, reproductive hormones, infectious diseases, and oncology
- Design and analysis of clinical trials in multiple clinical fields
- High Performance Liquid Chromatography
 - Hydrophobic Interaction
 - Reversed Phase
 - Ion Exchange
 - Gel Filtration
- Preparative Chromatography (through manufacturing scale)
- Crosslinking/Conjugation Chemistry
 - Homo and Heterobifunctional Linkers
 - Protein, Peptide, Small Molecule/Dye linkages
- Immobilization of Proteins on Solid Phases
- Matrix Formulations
- Factorial Design/Response Surface Modeling
- Statistical Analyses
- Spectroscopy
 - Visual
 - UV
 - Fluorescence
 - Chemiluminescence
- Gel Electrophoresis
- Characterization of Antibody-Antigen Kinetics on Pharmacia Biacore
- Western blots
- Product Optimization and Tolerance Analyses
- Product Validation
- Design Control & GMPs
- Material Compatibility Analysis
- Container Closure Integrity Analysis
- Physico-chemical Characterization
- Pharmacokinetic and Pharmacodynamic Analyses
- Biostatistics

Areas of Managerial Expertise

- Coordination of resources to design, manage, and analyze clinical trials and compose submissions to FDA
- Business Development and Strategic Alliances
- Project Management of Cross-functional teams
 - Lightweight Teams
 - Heavyweight Teams
- Technical Supervision
- Methods Research
- Product Feasibility
- Assay Development
- Process Development
- Product Development
- Participation/Leadership of Clinical Focus Groups
- Exploration of new clinical areas
 - Evaluation of potential Products
- Employee Career Development
- Performance Appraisal
- Negotiation Skills
 - Conflict Resolution
 - Cross-functional
- Total Quality Management (TQM)
- Contract Manufacturing

Patents/Inventions

Awarded a United States Patent for work at Hybritech on the invention: "Stabilized Internal Reference Calibrator for a Membrane-Based Device".

Awards

Two-time winner of Development Scientist of the Year award at Hybritech (1991, 1992)

Computer Skills

Expertise with Macintosh, IBM-compatible, and Mainframe computer systems. The software applications I am well-versed in are:

- System Software: Windows, OS X for Mac
- Spreadsheets: Microsoft Excel
- Experiment Design/Analysis: SAS/JMP, Design-Ease, Design-Expert, NCSS
- Statistical Analysis: SAS/JMP, MedCalc, PASS (sample size estimation), NCSS, SlimStat, Analyse-It
- Pharmacokinetics: Scientist 2.0, Summit PK 2.0
- Graphics: Kaleidagraph, MacFlow, Freehand, Adobe Photoshop, Kai's Power Tools, Bryce, Paint Alchemy, Terrazzo, Xres, Visio
- Multimedia: ProTools, StudioVision Pro
- Presentation: Powerpoint
- Word Processors: Word, WordPerfect
- Project Planning: MacProject Pro, Microsoft Project
- Web Design: Adobe GoLive Cyberstudio
- Instrument Software: HPLC, Biacore, Spectrophotometer, etc.

Publications

1. Evaluation of B7-H4 (DD-O110) as a prognostic marker in tissue and serum of ovarian cancer patients. Iris Simon, Nam Kim, Eleftherios P. Diamandis, Mark J. Sarno, and Robert L. Wolfert. Presented at 2005 American Association for Cancer Research meeting.
2. Circulating 1,5-anhydroglucitol levels in adult patients with diabetes mellitus reflect longitudinal changes of glycemia: a US trial of the GlycoMark™ assay. Janet B. McGill, Thomas G. Cole, William Nowatzke, Shannon Houghton, Erika B. Ammirati, Theresa Gautille, and Mark J. Sarno. *Diabetes Care* 2004;27:8:1859-1865.
3. Evaluation of an assay for 1,5-anhydroglucitol (Glycomark™) and determination of reference intervals on the Hitachi 917 analyzer. William Nowatzke, Mark Sarno, Nathan Birch, Douglas Stickle, Tanya Eden, and Thomas G Cole. *Clinica Chimica Acta* 2004;350:201-9.
4. Cln101 and Ovr110 as novel serum markers for detection of ovarian cancer. N. W. Kim, I. Simon, X. Duan, T. Kuo, L. Corral, A. Nguyen, R. A. Macina, M. J. Sarno, R. L. Wolfert, 2004 American Society of Clinical Oncology 40th Annual Meeting Proceedings;23:455.

5. Application of Novel and Traditional Serum Markers in Univariate and Multivariate Analysis to Improve the Sensitivity and Specificity of Cancer Detection. Iris Simon, Rong A. Fan, Charis E. Lawrenson, Xiaozhu Duan, Theresa Kuo, Laura Corral, Shirley Vong, David Lowe, Danny Terwey, Laurence Fayadat, Roberto Macina, Mark J. Sarno, Robert L. Wolfert, and Nam W. Kim. 2004 EDRN Annual Workshop Abstract.
6. Intermediate-term changes in serum 1,5-anhydroglucitol (GlycoMark) predict long-term changes in glycosylated hemoglobin (A1c) in patients with Type 1 and 2 diabetes mellitus. Sarno M, Cole T, Nowatzke W, McGill J. Presented at American Diabetes Association Annual Meeting, May 2004.
7. Application of Novel and Traditional Serum Biomarkers in Univariate and Multivariate Analysis to Improve the Sensitivity and Specificity of Cancer Detection. Iris Simon, Rong A. Fan, Xiaozhu Duan, Charis E. Lawrenson, Theresa Kuo, Laura Corral, Shirley Vong, David Lowe, Danny Terwey, Laurence Fayadat, Roberto Macina, Mark J. Sarno, Robert L. Wolfert, and Nam W. Kim. 2004 ISOBM Annual Meeting Abstract.
8. Detection of novel membrane protein in serum: Ovr110, a potential serum marker for early detection of ovarian cancer. Iris Simon, Nam W. Kim, Theresa Kuo, Laura Corral, Shirley Vong, David Lowe, Mark J. Sarno, Robert L. Wolfert. 2004 American Association of Cancer Research 95th Annual Meeting Proceedings;45:93.
9. Characterization of Lng105/napsin A in human serum: potential diagnostic utility in lung cancer. Rong A. Fan, Nam W. Kim, Daniel Bedinger, Paul Miller, Laurence Fayadat, Roberto Macina, Mark Sarno, Robert L. Wolfert. 2004 American Association of Cancer Research 95th Annual Meeting Proceedings;45:93.
10. Detection of Pro108/Spondin-2 protein in serum: A novel serum marker for cancer. Iris Simon, Charis A. Lawrenson, Nam W. Kim, Daniel Bedinger, Danny Terwey, Mark J. Sarno, Robert L. Wolfert. 2004 American Association of Cancer Research 95th Annual Meeting Proceedings;45:97.
11. Biological variability and specificity of lipoprotein-associated phospholipase A2 (Lp-PLA2), a novel marker of cardiovascular risk. Robert L. Wolfert, Nam W. Kim, Reed G. Selby, Mark J. Sarno, G. Russell Warnick, Krishnankutty Sudhir. Presented at American Heart Association 2004.
12. Serum 1,5-Anhydroglucitol (GlycoMark™), a New Potential Marker of Glycemia: A Longitudinal Study of Adult Patients with Diabetes Mellitus. Janet McGill, Thom Cole, William Nowatzke, Shannon Houghton, Theresa Gaultille, and Mark Sarno. Presented at Diabetes Technology and Therapeutics Annual Meeting, November 2003.
13. Pharmacokinetics and glucodynamics of rapid, short, and intermediate acting insulins: a randomized controlled trial comparing jet injection to needle syringe.

- Mark Sarno, Jo Bell, and Steve Edelman. *Diabetes Technology and Therapeutics* 2003;4:6:863-6.
14. Serum 1,5-anhydroglucitol (Glycomark™), a new marker of glycemia: cross-sectional comparison to established markers of glycemia in healthy subjects and patients with diabetes mellitus. Janet McGill, Thomas Cole, William Nowatzke, and Mark Sarno. Presented at American Diabetes Association Annual Meeting, June 2003.
 15. Technical Evaluation and Reference Interval Determination of 1,5-Anhydroglucitol using the GlycoMark(TM) Assay. Nowatzke WL, Sarno M, Stickle DF, Eden TR, Birch NC and Cole TG. *Clinical Chemistry* 2003; 49 (Supplement):A46.
 16. Toxicology and toxicokinetics of acute and subchronic administration of histamine dihydrochloride in rats. Linda Karavodin, Rodney Jensen, Mark Sarno, and Kurt Gehlsen. *Drug and Chemical Toxicology* 2003;26:1:35-49.
 17. Biological variability of lipoprotein-associated phospholipase A2 (Lp-PLA2), c-reactive protein (CRP), and traditional lipid markers of cardiovascular risk. Nam W. Kim, Mark J. Sarno, G. Russell Warnick, and Robert L. Wolfert. 2003 American College of Cardiology Annual Proceedings.
 18. Pharmacokinetics of histamine dihydrochloride: Implications for combined therapy with interleukin-2. Mark Middleton, Mark Sarno, Sanjiv S. Agarwala, John Glaspy, Aziz Laurent, Kelly McMasters, Peter Naredi, Steven O'Day, Eric Whitman, Sarah Danson, Rebecca Cosford, and Kurt Gehlsen; *Journal of Clinical Pharmacology* 2002;42:7:774-81.
 19. Histamine pharmacokinetics in tumor and host tissues after bolus-dose administration – a study in rat. Magnus Rizell, Peter Naredi, Per Lindner, Kristoffer Hellstrand, Mark Sarno, Per-Anders Jansson. *Life Sciences* 2002; 70:969-76.
 20. Excretion of sweat and urine pyridinoline crosslinks in healthy controls and subjects with established metabolic bone disease; Mark Sarno, Laura Sarno, David Baylink, Barbara Drinkwater, Sally Farley, Michael Kleerekoper, Robert Lang, Joan Lappe, Angelo Licata, Michael McClung, Paul Miller, Susan Natrass, Robert Recker, Elliot N. Schwartz, Fred Singer, Joseph R. Tucci, Richard Wasnich, Sandi Wolf, Helen Powell, Gayle Tjersland, and G. Russell Warnick. *Clinical Chemistry and Laboratory Medicine* 2001;39:3:223-8.
 21. Clinical immunogenicity of measles, mumps, and rubella vaccine MMRII delivered by the Injex jet injector: comparison with standard syringe injection; Mark Sarno, Erich Blase, Carl Schirmer, and Daniel Trujillo; *Pediatric Infectious Disease Journal* 2000; 19:9:839-42
 22. A collection method and high-sensitivity enzyme immunoassay for sweat pyridinoline and deoxypyridinoline crosslinks; Mark Sarno, Helen Powell, Gayle Tjersland, Donald Schoendorfer, Holden Harris, Kimberly Adams, Peggy Ogata, and G. Russell Warnick; *Clinical Chemistry* 1999; 45:9:1501-9.

23. Clinical utility of Osteopatch™ sweat pyridinoline; R. Nuti, R. Caudarella, E. Fiore, G. Isaia, X. Ortolani, G. Tjersland, M. Sarno, R. Warnick; Bone 1998;23:S627.
24. Osteopatch™ sweat pyridinoline is elevated in women with established osteoporosis; L. Sarno, D. Baylink, B. Drinkwater, S. Farley, M. Kleerekoper, J. Lappe, M. McClung, S. Nattrass, R. Recker, E. Schwartz, R. Wasnich, G. Tjersland, G. R. Warnick, M. Sarno; Bone 1998;23:S514.
25. Bone resorption markers quantified by sensitive immunoassays in non-occlusive multi-day Osteopatch™ sweat collections; G. Russell Warnick, Byron Doneen, Gayle Tjersland, Helen Powell, Mark Sarno, Holden Harris, Peggy Ogata, and Kim Adams; Journal of Bone and Mineral Research 1997;12:Supplement 1:S499.
26. Development of a serum ELISA for YKL-40 (Chondrex™) and it's application in Osteoarthritis; Sarno M.J., Scott T.A., Whaley J., Swindlehurst C.A., Price P.A., Cohen, P.; Arthritis & Rheumatism 1995;38:S240.
27. Characterization of a new enzyme immunoassay for Free Deoxypyridinoline in Serum, R. Nielsen, D. Broyles, S. Harvey, C. Shaffer, B. Bussett, M. Sarno, B. Kress. Journal of Bone and Mineral Research 1995;10:Supplement 1:S270.
28. Activation of a Rabbit Liver Progesterone 6-Beta-Hydroxylase by Substrate or Alpha Naphthoflavone, G. E. Schwab, M. Sarno, J. Singh, L. E. Vickery, E. F. Johnson. Presented at Federal Proceedings of the American Society of Biological Chemists, June 1986.
29. Genetic Evidence for Glucitol-Specific Enzyme III, an Essential Phosphocarrier Protein of the Salmonella typhimurium Glucitol Phosphotransferase System. Mark J. Sarno, L. Gregory Tenn, Anjana Desai, A. Michael Chin, Frank C. Grenier, and Milton H. Saier, Jr.; The Journal of Bacteriology 1984:953-5.

Manuscripts/Abstracts in-process:

1. Stability of lipoprotein-associated phospholipase A2 in normal individuals: a biovariability study. Nam Kim, Mark Sarno, Suzanne Lee, Aparna Lanka, Phil Pangilinan, and Robert Wolfert. In preparation for Clinical Chemistry.
2. B7-H4 is a novel membrane-bound protein and a candidate serum and tissue marker for ovarian cancer. Iris Simon, Shaoqiu Zhuo, Laura Corral, Eleftherios P. Diamandis, Mark J. Sarno, Robert L. Wolfert, and Nam W. Kim. Submitted to Cancer Research.